BIOASTER and Institut Pasteur are proud to join forces to build a novel microphysiological system (MPS) mimicking the first steps of immune activation during vaccination. This system will enable studying...
An important milestone has been reached for the GNA NOW Consortium, which BIOASTER is proud to be a partner of. A Go-decision has been received for the project’s NOSO-502 program...
New publication last week on Elsevier about: “Evolution of FMT – From early clinical to standardized treatments” Authors: Stephanie L Servetas 1, Phillip J Daschner 2, Cyril Guyard 3, Vincent Thomas 4, Herve Affagard 5, Chrysi Sergaki 6, Harry Sokol 7, Jennifer A Wargo 8, Gary...
BIOASTER wishes you a healthy & prosperous new year! “When the going gets tough, the tough get going” Thanks to our partners, founding members and teams for keeping on building...
Call for a unique opportunity in antibiotic community! The GNA NOW consortium (EU project) is looking for a novel antibiotic compound to progress to a clinical candidate. To find out...
Kaleido Biosciences and BIOASTER are glad to announce the successful completion of a collaborative project that provided new insights into ways Kaleido’s Microbiome Metabolic Therapies (MMT™) modulate the integrity and function of...
PiLeJe Laboratoire to collaborate with BIOASTER to investigate the health potential of a probiotic selection Pileje Laboratoire, a French company leader in probiotic-based dietary supplements in Europe and specialized in...
BIOASTER first shareholder with its two co-founders Adama OUATTARA and Wassim ABOU-JAOUDE of Gencovery. Wishing success to the first BIOASTER start-up. Gencovery provides cutting-edge software based on digital organisms for...
@BIOASTER receives $885K grant from the Bill & Melinda Gates Foundation @gatesfoundation to develop #Onchocerciasis advanced rapid #diagnostic with @mologic Ltd. BIOASTER, today announced it has received a grant in...
BioFilm Pharma and BIOASTER announced the signature of a research contract to address the challenge of antibiotic resistance. This collaboration will lead to the deciphering of the mode of action...
Kaleido Biosciences to collaborate with BIOASTER and MetaGenoPolis to investigate the health potential of a novel class of therapies targeting the microbiome. Kaleido Biosciences, a U.S.-based clinical-stage healthcare company, and...
BIOASTER announces a collaboration with Exeliom Biosciences, a leading biotech in the developement of innovative microbiome-based therapies, located in Paris and Dijon, France. The aim of the partnership is to...
By continuing browsing this website, you accept the use of cookies or other tracers for statistics of visits to optimize the functionality of the site, and or privacy policy. AcceptRejectRead More
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
